Tandem Diabetes Care (NSDQ:TNDM) said today that the FDA approved its t:slim X2 insulin pump with Dexcom‘s (NSDQ:DXCM) G5 mobile continuous glucose monitor.
The regulatory win makes the device the first sensor-augmented insulin pump cleared to let users make treatment decisions without pricking their finger, the company touted.
Get the full story at our sister site, Drug Delivery Business News.
The post Tandem Diabetes wins FDA nod for insulin pump with Dexcom’s CGM appeared first on MassDevice.